The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone - PubMed (original) (raw)
Review
The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone
B A Berkowitz. Clin Pharmacokinet. 1976.
Abstract
This review illustrates current approaches to the study of the disposition in man of the strong analagesics morphine and methadone and the narcotic antagonist naloxone. Morphine administered orally is rapidly absorbed but equally rapidly metabolised to morphine glucuronide. This contributes to the diminished oral efficacy of morphine. Following intramuscular administration morphine is very rapidly absorbed. After intravenous injection, the serum levels of morphine during the first 10 minutes are higher and more variable in older patients. The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient. Similar half-lives for morphine have been reported to normal volunteers and in anaethetised patients who received morphine. Thus, surgical anaesthesia may not markedly influence morphine half-life and disposition. Based on urinary excretion data in man, accelerated morphine metabolism and excretion do not contribute to morphine tolerance. Methadone is now widely used in the treatment of narcotic abuse. The half-life of methadone averages 25 hours. The prolonged retention of methadone in the plasma may be related to its extensive binding to plasma proteins. With chronic dosing, studies in both animals and man indicate an increase in the metabolism of methadone. Unlike morphine, the urinary excretion of methadone increases with acidification of the urine. Women may metabolise methadone to a greater extent than do men. With the exception of pupillary effects, the plasma levels of methadone correlate poorly with its pharmacological activity. There is a marked variation in methadone plasma levels between patients and within the same patient. Naloxone rapidly disappears from the serum in man and the initial distribution phase has a half-life of 4 minutes. The half-life of naloxone in serum following distribution is 64 minutes. Based on animal studies, the rapid onset of the narcotic antagonist action of naloxone can be related to its rapid entry into the brain, whereas its potency stems in part from its high lipid solubility which allows a high brain concentration to be achieved. The short duration of action of naloxone may result from its rapid egress from the brain.
Similar articles
- Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action.
Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Ngai SH, et al. Anesthesiology. 1976 May;44(5):398-401. doi: 10.1097/00000542-197605000-00008. Anesthesiology. 1976. PMID: 1267205 - Disposition of naloxone: use of a new radioimmunoassay.
Berkowitz BA, Ngai SH, Hempstead J, Spector S. Berkowitz BA, et al. J Pharmacol Exp Ther. 1975 Dec;195(3):499-504. J Pharmacol Exp Ther. 1975. PMID: 1195133 - High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
Säwe J. Säwe J. Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review. - Interactions between narcotic analgesics and benzodiazepine derivatives on behavior in the mouse.
Shannon HE, Holtzman SG, Davis DC. Shannon HE, et al. J Pharmacol Exp Ther. 1976 Nov;199(2):389-99. J Pharmacol Exp Ther. 1976. PMID: 10428 - Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
Johnsson G, Regàrdh CG. Johnsson G, et al. Clin Pharmacokinet. 1976;1(4):233-63. doi: 10.2165/00003088-197601040-00001. Clin Pharmacokinet. 1976. PMID: 13958 Review.
Cited by
- Characterizing the opioidergic mechanisms of repetitive transcranial magnetic stimulation-induced analgesia: a randomized controlled trial.
Liu Y, Sun J, Wu C, Ren J, He Y, Sun N, Huang H, Chen Q, Liu D, Huang Y, Xu F, Yu L, Fitzgibbon BM, Cash RFH, Fitzgerald PB, Yan M, Che X. Liu Y, et al. Pain. 2024 Sep 1;165(9):2035-2043. doi: 10.1097/j.pain.0000000000003220. Epub 2024 Mar 26. Pain. 2024. PMID: 38537053 Free PMC article. Clinical Trial. - Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
Saari TI, Strang J, Dale O. Saari TI, et al. Clin Pharmacokinet. 2024 Apr;63(4):397-422. doi: 10.1007/s40262-024-01355-6. Epub 2024 Mar 14. Clin Pharmacokinet. 2024. PMID: 38485851 Free PMC article. Review. - Effects of GABAB receptor blockade on lateral habenula glutamatergic neuron activity following morphine injection in the rat: an electrophysiological study.
Amohashemi E, Alaei H, Reisi P. Amohashemi E, et al. Res Pharm Sci. 2022 Dec 24;18(1):16-23. doi: 10.4103/1735-5362.363592. eCollection 2023 Feb. Res Pharm Sci. 2022. PMID: 36846735 Free PMC article. - Dedicated nursing care pathway improved management of opioid-poisoned patients in the emergency department: A before-after observational study.
Isoardi K, Learmont B, Horan B, Isbister G. Isoardi K, et al. Emerg Med Australas. 2023 Feb;35(1):69-73. doi: 10.1111/1742-6723.14056. Epub 2022 Aug 15. Emerg Med Australas. 2023. PMID: 35970763 Free PMC article. - Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders.
Ruíz Ruíz JJ, Martinez Delgado JM, García-Marchena N; ANDOPIO Study Group. Ruíz Ruíz JJ, et al. Harm Reduct J. 2021 Apr 13;18(1):41. doi: 10.1186/s12954-021-00488-2. Harm Reduct J. 2021. PMID: 33849574 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources